VivoSeq
0

Pipeline Programs

56

Active Trials

117

Companies Involved

ESS is an early-stage landscape with 0 programs across 117 companies. The most active players are AstraZeneca, GSK, Pfizer.

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

41/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

770

clinical trials

Completed456 · 59%
Unknown status68 · 9%
No longer available62 · 8%
Terminated46 · 6%
Available40 · 5%
Recruiting33 · 4%
Other65 · 8%

Trial Activity

770 trials

Short Title: Standard vs. Lower Pressure Pneumoperitoneum
Recruiting··N/A·NCT06338865·294 enrolled
The Avenues Study: Dual Use Cessation
Recruiting·UUniversity of Wisconsin, Madison·Phase 4·NCT06474299·500 enrolled
Assessment of Synaptic Density in MS
Recruiting··Phase 1·NCT04634994·30 enrolled
Graded Insulin Suppression Test P&F
Recruiting··Phase 1·NCT06592261·15 enrolled
The PEERLESS II Study
Recruiting·IInari Medical·N/A·NCT06055920·1,200 enrolled
Page 1 of 52

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)